Variants in the solute carrier organic anion transporter family member 1A2 (SLCO1A2) have been reported to be associated with statin-induced myopathy and progressive supranuclear palsy, an uncommon brain disorder that affects, among others, movement, control of walking (gait) and balance. The gene discussed is SLCO1A2; the disease is progressive supranuclear palsy.